Amir Toor

Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants.

ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning.

Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations.

Infection--an underappreciated cause of bone pain in multiple myeloma.

BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.

Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma.

Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines.

Post-transplant air-leak syndrome.

Cardiac nonamyloidotic immunoglobulin deposition disease.

Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity.

The administration of polymerized human hemoglobin (Pyridoxylated) to a Jehovah's Witness after submyeloablative stem cell transplantation complicated by delayed graft failure.

Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma.

Impaired NHEJ function in multiple myeloma.

Dose intense therapy for relapsed lymphoproliferative disorders: the more things change, the more they are the same.

Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding.

Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation.

Comment on "Cutting edge: CD8+ T cell priming in the absence of NK cells leads to enhanced memory responses".

Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.

Favorable Outcomes in Patients with High Donor-Derived T Cell Count after in Vivo T Cell-Depleted Reduced-Intensity Allogeneic Stem Cell Transplantation.